Skip to main content

Month: March 2020

Elis – Résultats annuels 2019

 Résultats annuels 2019 très satisfaisantsCroissance organique record, solidité de la marge d’EBITDA, augmentation significative du résultat net courant et du free cash-flowTrès bonne performance financière du Groupe en 2019Chiffre d’affaires record à 3 281,8m€ (+4,7% dont +3,3% de croissance organique)Marge d’EBITDA à 33,6% du chiffre d’affaires (31,5% en excluant l’impact IFRS16, stable vs 2018)Résultat net courant de 256m€ (260m€ en excluant l’impact IFRS16, soit +16% vs 2018)Free cash-flow de 247m€ (186m€ en excluant l’impact IFRS 16, soit +21% vs 2018)Amélioration du levier d’endettement à 3,2x au 31 décembre 2019Succès opérationnels dans toutes les zones géographiques, reflétant la pertinence de la stratégie d’ElisHausses de prix satisfaisantes dans les pays sujets à une forte inflation de leur base de coûtsTrès bonne dynamique...

Continue reading

CFO Sarah Kuijlaars leaves Arcadis

Amsterdam, 4 March 2020 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, today announced the resignation of Sarah Kuijlaars, Chief Financial Officer (CFO) and Member of the Executive Board, effective 4 March 2020.Sarah Kuijlaars, who joined Arcadis as CFO in April 2018, is leaving Arcadis for personal reasons and in mutual agreement. Consequently, the Supervisory Board will initiate the process to appoint a new CFO for the next stage of Arcadis’ development.“We thank Sarah for her contribution to Arcadis in the past two years. Under her financial leadership we created a strong balance sheet and a solid financial foundation for future growth”, said Peter Oosterveer, CEO and Chairman of the Executive Board.Niek Hoek, Chairman of the Supervisory Board,...

Continue reading

FDA grants Breakthrough Device Designation for Roche’s Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma

The Elecsys GALAD score aims to support clinicians in diagnosing hepatocellular carcinoma by giving them more timely and accurate information to make earlier interventionsWhen hepatocellular carcinoma is detected and managed at the very earliest, patient’s 5-year survival rates can increase to over 70%1Utilizing blood-based biomarkers, as part of the Elecsys GALAD score, is minimally invasive to patientsBasel, 4 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys® GALAD score.* This algorithmic score combines gender and age with the biomarker results of the Elecsys AFP, AFP-L3 and PIVKA-II and is intended to aid diagnosis of early stage hepatocellular carcinoma (HCC).The Elecsys GALAD score will be the first GALAD...

Continue reading

Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis

Marketing Authorization Application (MAA) based on data from the head-to-head OPTIMUM Phase 3 study, presented at the 35th Congress of The European Committee for Treatment and Research in Multiple SclerosisIdorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have a revenue-sharing agreement in respect to ponesimodAllschwil, Switzerland – March 4, 2020Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a MAA to the European Medicines Agency (EMA) seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).For further details please read the full announcement available here:https://johnsonandjohnson.gcs-web.com/static-files/8444902a-4913-4258-bb4c-7d60f9db257fAbout...

Continue reading

Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis

Marketing Authorization Application (MAA) based on data from the head-to-head OPTIMUM Phase 3 study, presented at the 35th Congress of The European Committee for Treatment and Research in Multiple SclerosisIdorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have a revenue-sharing agreement in respect to ponesimodAllschwil, Switzerland – March 4, 2020Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a MAA to the European Medicines Agency (EMA) seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).For further details please read the full announcement available here:https://johnsonandjohnson.gcs-web.com/static-files/8444902a-4913-4258-bb4c-7d60f9db257fAbout...

Continue reading

Hoivatilat Plc: Hoivatilat Plc has published its Annual Report 2019

Hoivatilat PlcStock Exchange Release 4 March 2020 at 8:00 a.m. EETHoivatilat Plc has published its Annual Report 2019Hoivatilat has published its Annual Report 2019 at https://hoivatilat.fi/en/for-investors/reports-and-presentations/. The Annual Report is also attached to this release in PDF format.The Annual Report 2019 contains the Report of the Board of Directors, Group Financial Statements, Auditor’s Report Hoivatilat’s Corporate Governance Statement.Further information:Riikka SäkkinenHR and Communications Managertel. +358 40 524 2768Hoivatilat in brief:Hoivatilat Plc specialises in producing, developing, owning and leasing out nursing homes, day care centres, schools and service communities. Founded in 2008, the company has been working in cooperation with as many as 60 Finnish municipalities and has launched 200 property...

Continue reading

UPDATE – Zoom Announces International Expansion for Zoom Phone in 11 Additional Countries (Total 17 Countries and One Territory Now), Beta Service in 24 New Countries and One Territory, and Adds to Multi-Lingual Prompt Support

SAN JOSE, Calif., March 03, 2020 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ:ZM) today announced general availability of its Zoom Phone cloud phone service in 11 additional countries (Total 17 countries and one territory now) and Beta Service in 24 new countries and one territory.Zoom Phone now supports local phone numbers and PSTN access with new Metered and Unlimited Calling Plans in Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Sweden, and Switzerland. This expanded geographic coverage allows Zoom customers all over the world to migrate away from their in-country legacy phone systems to consolidate business communications into Zoom’s all-in-one, video-first unified communications platform.Zoom Phone Beta Service will also be available to existing qualified Zoom customers upon...

Continue reading

Kayne Anderson MLP/Midstream Investment Company Provides Unaudited Balance Sheet Information and Announces its Net Asset Value and Asset Coverage Ratios at February 29, 2020

HOUSTON, March 03, 2020 (GLOBE NEWSWIRE) — Kayne Anderson MLP/Midstream Investment Company (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of February 29, 2020.As of February 29, 2020, the Company’s net assets were $1.5 billion, and its net asset value per share was $11.85. As of February 29, 2020, the Company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 381% and the Company’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 250%.       Long-term investments were comprised of Midstream MLP (69%), Midstream Company (29%), and Renewable Infrastructure/Utility...

Continue reading

Advantest将于3月10-11日举行虚拟展会以在新冠疫情肆虐之下继续提供IC测试信息

东京, March 04, 2020 (GLOBE NEWSWIRE) — 半导体测试设备领先供应商Advantest  Corporation(TSE:6857)将于3月10-11日组织一次虚拟展会以与全球客户共享宝贵的技术和市场数据,同时避免与会者暴露于潜在冠状病毒(COVID-19)疾病的风险。借助网络会议,Advantest的技术专家将展示最新的半导体测试技术和最佳实践,并与战略合作伙伴及现有和潜在客户进行互动。此外,代表电子制造供应链的全球工业组织SEMI的两位高管将在在线论坛上畅谈行业状况和市场前景。“虽然因冠状病毒疫情的爆发而取消了许多行业展会和会议,但我们开发了这个虚拟展会来提高人们对当今最先进的半导体测试解决方案的认识。”Advantest全球营销传播副总裁Judy Davies表示。“在我们努力通过国际活动及时分享相关信息来支持客户的过程中,SEMI的参与并提供真知灼见显得非常及时。”“因为Advantest转向在线交流以确保与会者的安全并通过关键的行业见解来保持先进信息的自由交流,SEMI非常高兴能参加此次虚拟展会。”SEMI总裁兼首席执行官Ajit Manocha表示。3月10-11日,Advantest的创新虚拟展会将有九位国际演讲者组成的专题演讲以各种语言分享其专业见解。为了促进演讲信息的广泛使用,会议将以英语、汉语和韩语进行。每次会议均采用互动形式,为参会成员提供提问机会。所有会议都会被录制并将在为期两天的活动结束之后在线发布,以供大家继续参考。此次虚拟展会的议程如下所示:3月10日星期二 太平洋夏令时(PDT)上午8:00独立(SA)和非独立(NSA)5G NR设备测试:MIMO和载波聚合(英文)Advantest集团公司W2BI总裁Dinesh Doshi太平洋夏令时下午5:00欢迎致辞和概述(英语)Advantest全球营销传播副总裁Judy Davies太平洋夏令时下午5:30SEMI最新动态(英文)SEMI总裁兼首席执行官Ajit...

Continue reading

儘管受到新型冠狀病毒疫情影響,Advantest 仍會在 3 月 10 日至 11 日進行虛擬貿易展繼續提供 IC 測試資訊

東京, March 04, 2020 (GLOBE NEWSWIRE) — 東京 2020 年 3 月 3 日 (GLOBE NEWSWIRE) — 領先全球的半導體測試設備供應商 Advantest Corporation(TSE:6857)將於 3 月 10 日至 11 日舉辦虛擬貿易展覽會,與全球客戶共享寶貴的技術和市場數據,此舉亦能避免感染新型冠狀病毒(COVID-19)所帶來的潛在疾病風險。通過網絡會議,Advantest 的技術專家將展示最新的半導體測試技術和最佳實踐,並與戰略合作夥伴、現有及潛在客戶進行互動。 此外,在線論壇將有 SEMI 的兩位高級管理人員作為代表,討論行業狀況和市場前景,SEMI 是代表電子製造供應鏈的全球業界組織。Advantest 全球營銷傳播副總裁 Judy Davies 說 :「儘管因冠狀病毒爆發,許多行業取消了貿易展覽和會議,但我們開發了這個虛擬貿易展覽會,以提高人們對當今最先進的半導體測試解決方案的認識」。 「我們通過國際活動及時共享相關資訊而得以支持客戶,同時讓 SEMI 參與其中並提供見解是非常合適的。」「隨著 Advantest 轉向在線交流以確保參與會議人員的安全,並通過 重要的業界見解,向我們全球成員維持有利資訊的自由流通,SEMI 很高興能夠參加此虛擬貿易展覽會」SEMI 總裁兼行政總裁 Ajit Manocha 表示。3 月 10 日至 11 日,Advantest 的創新虛擬貿易展將由九位國際級講員組成的專題講座,以各種語言分享他們的專業見解。 為了促進所介紹資訊的廣泛使用,會議將以英語、普通話及韓語進行。每個環節都是互動的,為聽眾提供了提問的機會。 在為期兩天的活動之後,所有會議都將被記錄並在網上發佈,以供繼續參考。虛擬貿易展的議程為:3 月 10 日,星期二上午 8:00 太平洋夏令時間 (PDT)獨立 (SA) 及非獨立 (NSA) 5G NR 設備測試:MIMO 和 Carrier...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.